Doctor of Osteopathy Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Michael Burnett

Pulmonary Disease Lansing, MI Doctor of Osteopathy

NPI 1730169418 CMS profile 351596

1200 E Michigan Ave, Suite 415, Lansing, MI 48912

Open in the dashboard

General payments

$3,389

203 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Michael Burnett of Lansing, MI is reported in the CMS Open Payments database as having received $3,389 across 203 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $1,009 59
2020 General $1,227 72
2019 General $1,154 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Burnett
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michael Burnett were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michael Burnett Pulmonary Disease median Middle half National median
2019 $1,154 $377 $109–$1,340 $163
2020 $1,227 $230 $56–$907 $114
2021 $1,009 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $760 42 payments
  2. AstraZeneca Pharmaceuticals LP $602 31 payments
  3. Grifols USA, LLC $482 30 payments
  4. GlaxoSmithKline, LLC. $364 37 payments
  5. Mylan Specialty L.P. $198 11 payments
  6. Genzyme Corporation $158 8 payments
  7. Insmed, Inc. $131 3 payments
  8. Genentech USA, Inc. $91 6 payments
  9. Actelion Pharmaceuticals US, Inc. $86 5 payments
  10. Regeneron Healthcare Solutions, Inc. $75 5 payments
  11. Other $443 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $3,289 202 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2021
  1. OFEV $597 28 payments
  2. Prolastin-C Liquid $482 30 payments
  3. SPIRIVA RESPIMAT $437 26 payments
  4. SYMBICORT $321 16 payments
  5. TRELEGY ELLIPTA $163 21 payments
  6. Yupelri $144 8 payments
  7. STIOLTO RESPIMAT $135 10 payments
  8. Arikayce $131 3 payments
  9. NUCALA $111 9 payments
  10. DUPIXENT $100 5 payments
  11. Other $1,465 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record